|
CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL). |
|
|
Stock and Other Ownership Interests - Amarin Corporation; Bellicum Pharmaceuticals; Mazor Robotics; Transenterix |
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech; HUYA Bioscience International; Immunocore; Merck; Regeneron |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst) |
|
|
Consulting or Advisory Role - Celgene; CureVac; Nektar |
Research Funding - Celgene (Inst); Idera (Inst); Nektar (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Nektar |
|
|
Consulting or Advisory Role - Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Genmab; Idera; Immunocore; Incyte; MedImmune; Merck Serono; Merck Sharp & Dohme; Newlink Genetics; Novartis; Pierre Fabre; Roche/Genentech; Sandoz; Sanofi; Sun Pharma; Syndax; Ultimovacs |
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Merck Sharp & Dohme |
|
|
Honoraria - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess |
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Boston Biomedical; Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; Imugene; Incyte; iOncologi; Ipsen; Kyocera; Merck Serono; MSD; Nektar; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra; Vitaccess |
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Merck; Merck Serono |
Consulting or Advisory Role - Amgen |
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche/Genentech |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst) |
Travel, Accommodations, Expenses - Roche/Genentech |
|
|
Stock and Other Ownership Interests - Actym Therapeutics; Adaptive Biotechnologies; Amphivena; Intensity Therapeutics; Torque |
Consulting or Advisory Role - Abbvie; Adaptimmune; Allakos; Almac Diagnostics; Array BioPharma; AstraZeneca/MedImmune; Biodesix; Bristol-Myers Squibb; Celldex; Genentech/Roche; Genmab; Gritstone Bio; Hinge Bio; immunocore; Incyte; Innate Pharma; Inovio Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck Sharp & Dohme; Modulate Pharma; Molecular Partners; Nektar; Newlink Genetics; Novartis; Omniox; Pieris Pharmaceuticals; Pierre Fabre; Seagen; Symphogen; Theravance; Torque |
Other Relationship - AcademicCME; Clinical Care Options; Dava Oncology; Haymarket Media; Imedex; Physicans' Education Resource; Prime Oncology; Research to Practice; TRM Oncology; Vindico |
|
|
No Relationships to Disclose |
|
|
Employment - AstraZeneca; Bristol-Myers Squibb (Mexico) |
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
Other Relationship - Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - Aduro Biotech; Agena Bioscience; Amgen; BMS Brazil; Merck; Novartis; OncoSec; Pierre Fabre; Roche |
Research Funding - BMS Brazil; Merck |